Phase 3 Data on CUBICIN Published in Journal Clinical Infectious Diseases; CUBICIN Efficacy Comparable to Standards of Care Against MSSA and MRSA.
Linked as:
Extract
Phase 3 Data on CUBICIN Published in Journal Clinical Infectious Diseases; CUBICIN Efficacy Comparable to Standards of Care Against MSSA and MRSA.
LEXINGTON, Mass. -- Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced that data from its two pivotal Phase 3 trials studying the safety and efficacy of its flagship antibiotic product Cubicin(R) (daptomycin for injection) have been published in the June 15 issue of Clinical Infectious Diseases (CID). CUBICIN, the first...
See the full content of this document
Sponsored links
